Esperion to be Acquired by ARCHIMED in $1.1 Billion Deal
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ESPR?
Source: NASDAQ.COM
- Acquisition Overview: Esperion Therapeutics has announced an agreement to be acquired by funds managed by ARCHIMED in a deal valued at up to $1.1 billion, expected to close in the third quarter, marking the company's transition to private ownership and delisting from Nasdaq.
- Shareholder Benefit Analysis: Under the agreement, Esperion shareholders will receive $3.16 per share in cash at closing, representing a 58% premium over the closing price on April 30, along with a non-tradeable contingent value right potentially worth up to $100 million in milestone payments.
- Sales Targets and Incentives: The contingent payments are tied to future U.S. net sales, with shareholders eligible for up to $40 million if bempedoic acid products (including NEXLETOL and NEXLIZET) exceed $350 million in sales by 2027, and a $60 million payment if bumetanide products (including ENBUMYST) reach or exceed $160 million in annual sales through 2030.
- Market Outlook and Strategic Significance: ARCHIMED partner Justin Bateman stated that Esperion has a strong foundation in cardiovascular and primary care markets, and the acquisition is expected to support the company's future growth, with the board unanimously approving the deal and recommending shareholders vote in favor.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ESPR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ESPR
Wall Street analysts forecast ESPR stock price to rise
5 Analyst Rating
4 Buy
0 Hold
1 Sell
Moderate Buy
Current: 2.000
Low
1.72
Averages
7.94
High
16.00
Current: 2.000
Low
1.72
Averages
7.94
High
16.00
About ESPR
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering cardiometabolic and rare/orphan disease therapies. It markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels who are at risk of cardiovascular disease and nasal spray, loop diuretic for the treatment of edema associated with congestive heart failure, and hepatic and renal disease. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. NEXLETOL is a first-in-class ACLY inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating LDL receptors. NEXLIZET contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and cholesterol absorption in the intestine. Its Enbumyst is the FDA-approved nasal spray loop diuretic.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Esperion Therapeutics Shares Surge 57% on $1.1 Billion Acquisition by ARCHIMED
- Acquisition Agreement: Esperion Therapeutics has agreed to be acquired by ARCHIMED for up to $1.1 billion, with shareholders set to receive $3.16 per share in cash plus contingent value rights tied to future sales milestones worth up to $100 million, reflecting confidence in the company's growth prospects.
- Stock Surge: Following the acquisition announcement, Esperion's shares jumped approximately 57% in premarket trading, indicating a strong market reaction to the 58% premium offered and investor optimism regarding the company's future post-privatization.
- Transaction Timeline: The deal has been approved by Esperion's board and is expected to close in the third quarter of 2026, pending shareholder and regulatory approvals, demonstrating the company's commitment to strategic transformation.
- Financial Performance Overview: Although Esperion's recent earnings report showed a GAAP EPS of $0.22, missing expectations by $0.05, its revenue of $168.45 million exceeded forecasts by $2.33 million, highlighting the company's ongoing growth potential in the cardiometabolic sector.
See More
Esperion to be Acquired at 58% Premium, Shareholders to Receive $3.16
- Acquisition Overview: Esperion has signed an acquisition agreement with Archimed for $1.1 billion, allowing shareholders to receive $3.16 per share in cash at closing, representing a 58% premium over Thursday's closing price, which provides shareholders with attractive immediate value while also offering potential upside through future milestone payments.
- Future Growth Potential: The agreement includes contingent milestone payments of up to $100 million tied to U.S. sales performance of key products, including cholesterol treatments like Nexletol and Nexlizet, which will support the company's future financial performance and growth prospects.
- Market Reaction: Following the acquisition announcement, Esperion shares surged 58% in pre-market trading on Friday and are on track to breach their 100-day moving average for the first time in nearly two months, indicating positive investor sentiment despite the stock being down over 50% year-to-date.
- Company Outlook: The acquisition is expected to close in the third quarter of 2026, after which Esperion will become a privately held company and be delisted from Nasdaq; CEO Sheldon Koenig emphasized that this acquisition not only provides immediate value to shareholders but also retains the opportunity for additional upside through the growth of core products.
See More
Esperion to be Acquired by ARCHIMED in $1.1 Billion Deal
- Acquisition Overview: Esperion Therapeutics has announced an agreement to be acquired by funds managed by ARCHIMED in a deal valued at up to $1.1 billion, expected to close in the third quarter, marking the company's transition to private ownership and delisting from Nasdaq.
- Shareholder Benefit Analysis: Under the agreement, Esperion shareholders will receive $3.16 per share in cash at closing, representing a 58% premium over the closing price on April 30, along with a non-tradeable contingent value right potentially worth up to $100 million in milestone payments.
- Sales Targets and Incentives: The contingent payments are tied to future U.S. net sales, with shareholders eligible for up to $40 million if bempedoic acid products (including NEXLETOL and NEXLIZET) exceed $350 million in sales by 2027, and a $60 million payment if bumetanide products (including ENBUMYST) reach or exceed $160 million in annual sales through 2030.
- Market Outlook and Strategic Significance: ARCHIMED partner Justin Bateman stated that Esperion has a strong foundation in cardiovascular and primary care markets, and the acquisition is expected to support the company's future growth, with the board unanimously approving the deal and recommending shareholders vote in favor.
See More
Esperion Enters Acquisition Agreement with ARCHIMED
- Acquisition Overview: Esperion Therapeutics has entered into an agreement with ARCHIMED, under which ARCHIMED will acquire Esperion for $3.16 per share in cash, valuing the transaction at approximately $1.1 billion, reflecting strong confidence in Esperion's future growth.
- Shareholder Value Assurance: Esperion shareholders will receive $3.16 per share in cash at closing, along with rights to participate in up to $100 million in contingent milestone payments tied to future sales performance, ensuring shareholders benefit from the company's growth.
- Market Growth Prospects: The acquisition by ARCHIMED will provide Esperion with robust financial support to further develop its presence in cardiovascular and primary care markets, expected to enhance the company's leadership in global cardiovascular disease treatment.
- Approval and Future Plans: The transaction has been unanimously approved by Esperion's Board of Directors and is expected to close in the third quarter of 2026, at which point Esperion will become a privately held company and its stock will no longer be listed on Nasdaq.
See More
Esperion Reports 38% Revenue Growth and Enbumyst Launch Plans at Needham Conference
- Significant Revenue Growth: Esperion reported a 38% year-over-year revenue increase, indicating strong performance in the cardiovascular drug market, which is expected to further solidify its market position in lipid-lowering therapies.
- New Product Launch Plans: The company plans to deploy 155 sales representatives by May 1, aiming for a full commercial launch of Enbumyst by September 2025, targeting fluid management for heart failure patients to reduce hospital readmission rates.
- Acquisition Strategy: Esperion acquired Corstasis for an upfront payment of $75 million, with up to $180 million in sales milestones and a 15% royalty on worldwide net sales, providing financial support for expanding its product portfolio.
- Guideline Update Impact: The recent treatment guidelines provide multiple Class 1A recommendations for Esperion's NEXLETOL and NEXLIZET, which is expected to drive further penetration in the lipid-lowering market, particularly among primary prevention and statin-intolerant patients.
See More
Esperion Outlines Future Growth Plans and Acquisition Strategy
- Market Penetration Plans: Esperion aims to enhance its U.S. market penetration through strengthened collaborations with global partners, which is expected to increase its market share in the cardiovascular sector, thereby bolstering its position in the competitive pharmaceutical landscape.
- Financial Performance Analysis: Despite reporting an EPS of $0.22 in Q4, below Wall Street's expectation of $0.28, and revenue of $168.5 million, CEO emphasized that 2025 will be a defining year for growth, reflecting confidence in future prospects.
- Acquisition Strategy: Esperion's acquisition of Corstasis Therapeutics for $75 million is anticipated to create long-term value and advance its Vision 2040 strategy, aiming to grow both franchises to multi-billion-dollar potential.
- Investor Sentiment: Although the stock fell over 6% post-report, retail sentiment on Stocktwits remained 'extremely bullish', indicating optimism about Esperion's upcoming growth catalysts.
See More
Esperion Therapeutics Shares Surge 57% on $1.1 Billion Acquisition by ARCHIMED
- Acquisition Agreement: Esperion Therapeutics has agreed to be acquired by ARCHIMED for up to $1.1 billion, with shareholders set to receive $3.16 per share in cash plus contingent value rights tied to future sales milestones worth up to $100 million, reflecting confidence in the company's growth prospects.
- Stock Surge: Following the acquisition announcement, Esperion's shares jumped approximately 57% in premarket trading, indicating a strong market reaction to the 58% premium offered and investor optimism regarding the company's future post-privatization.
- Transaction Timeline: The deal has been approved by Esperion's board and is expected to close in the third quarter of 2026, pending shareholder and regulatory approvals, demonstrating the company's commitment to strategic transformation.
- Financial Performance Overview: Although Esperion's recent earnings report showed a GAAP EPS of $0.22, missing expectations by $0.05, its revenue of $168.45 million exceeded forecasts by $2.33 million, highlighting the company's ongoing growth potential in the cardiometabolic sector.
See More
Esperion to be Acquired at 58% Premium, Shareholders to Receive $3.16
- Acquisition Overview: Esperion has signed an acquisition agreement with Archimed for $1.1 billion, allowing shareholders to receive $3.16 per share in cash at closing, representing a 58% premium over Thursday's closing price, which provides shareholders with attractive immediate value while also offering potential upside through future milestone payments.
- Future Growth Potential: The agreement includes contingent milestone payments of up to $100 million tied to U.S. sales performance of key products, including cholesterol treatments like Nexletol and Nexlizet, which will support the company's future financial performance and growth prospects.
- Market Reaction: Following the acquisition announcement, Esperion shares surged 58% in pre-market trading on Friday and are on track to breach their 100-day moving average for the first time in nearly two months, indicating positive investor sentiment despite the stock being down over 50% year-to-date.
- Company Outlook: The acquisition is expected to close in the third quarter of 2026, after which Esperion will become a privately held company and be delisted from Nasdaq; CEO Sheldon Koenig emphasized that this acquisition not only provides immediate value to shareholders but also retains the opportunity for additional upside through the growth of core products.
See More
Esperion to be Acquired by ARCHIMED in $1.1 Billion Deal
- Acquisition Overview: Esperion Therapeutics has announced an agreement to be acquired by funds managed by ARCHIMED in a deal valued at up to $1.1 billion, expected to close in the third quarter, marking the company's transition to private ownership and delisting from Nasdaq.
- Shareholder Benefit Analysis: Under the agreement, Esperion shareholders will receive $3.16 per share in cash at closing, representing a 58% premium over the closing price on April 30, along with a non-tradeable contingent value right potentially worth up to $100 million in milestone payments.
- Sales Targets and Incentives: The contingent payments are tied to future U.S. net sales, with shareholders eligible for up to $40 million if bempedoic acid products (including NEXLETOL and NEXLIZET) exceed $350 million in sales by 2027, and a $60 million payment if bumetanide products (including ENBUMYST) reach or exceed $160 million in annual sales through 2030.
- Market Outlook and Strategic Significance: ARCHIMED partner Justin Bateman stated that Esperion has a strong foundation in cardiovascular and primary care markets, and the acquisition is expected to support the company's future growth, with the board unanimously approving the deal and recommending shareholders vote in favor.
See More
Esperion Enters Acquisition Agreement with ARCHIMED
- Acquisition Overview: Esperion Therapeutics has entered into an agreement with ARCHIMED, under which ARCHIMED will acquire Esperion for $3.16 per share in cash, valuing the transaction at approximately $1.1 billion, reflecting strong confidence in Esperion's future growth.
- Shareholder Value Assurance: Esperion shareholders will receive $3.16 per share in cash at closing, along with rights to participate in up to $100 million in contingent milestone payments tied to future sales performance, ensuring shareholders benefit from the company's growth.
- Market Growth Prospects: The acquisition by ARCHIMED will provide Esperion with robust financial support to further develop its presence in cardiovascular and primary care markets, expected to enhance the company's leadership in global cardiovascular disease treatment.
- Approval and Future Plans: The transaction has been unanimously approved by Esperion's Board of Directors and is expected to close in the third quarter of 2026, at which point Esperion will become a privately held company and its stock will no longer be listed on Nasdaq.
See More
Esperion Reports 38% Revenue Growth and Enbumyst Launch Plans at Needham Conference
- Significant Revenue Growth: Esperion reported a 38% year-over-year revenue increase, indicating strong performance in the cardiovascular drug market, which is expected to further solidify its market position in lipid-lowering therapies.
- New Product Launch Plans: The company plans to deploy 155 sales representatives by May 1, aiming for a full commercial launch of Enbumyst by September 2025, targeting fluid management for heart failure patients to reduce hospital readmission rates.
- Acquisition Strategy: Esperion acquired Corstasis for an upfront payment of $75 million, with up to $180 million in sales milestones and a 15% royalty on worldwide net sales, providing financial support for expanding its product portfolio.
- Guideline Update Impact: The recent treatment guidelines provide multiple Class 1A recommendations for Esperion's NEXLETOL and NEXLIZET, which is expected to drive further penetration in the lipid-lowering market, particularly among primary prevention and statin-intolerant patients.
See More
Esperion Outlines Future Growth Plans and Acquisition Strategy
- Market Penetration Plans: Esperion aims to enhance its U.S. market penetration through strengthened collaborations with global partners, which is expected to increase its market share in the cardiovascular sector, thereby bolstering its position in the competitive pharmaceutical landscape.
- Financial Performance Analysis: Despite reporting an EPS of $0.22 in Q4, below Wall Street's expectation of $0.28, and revenue of $168.5 million, CEO emphasized that 2025 will be a defining year for growth, reflecting confidence in future prospects.
- Acquisition Strategy: Esperion's acquisition of Corstasis Therapeutics for $75 million is anticipated to create long-term value and advance its Vision 2040 strategy, aiming to grow both franchises to multi-billion-dollar potential.
- Investor Sentiment: Although the stock fell over 6% post-report, retail sentiment on Stocktwits remained 'extremely bullish', indicating optimism about Esperion's upcoming growth catalysts.
See More
